NCT06230900View on ClinicalTrials.gov

Mass Balance of Orally Administered [14C] (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

April 19, 2025

Study Completion Date

April 19, 2025

Conditions
Energy IntakeEnergy Metabolism
Interventions
OTHER

(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one

(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one ingestion

COMBINATION_PRODUCT

14C-(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one

14C (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one ingestion

Trial Locations (1)

6708PB

Wageningen University and Research, Wageningen

All Listed Sponsors
collaborator

TNO

OTHER

collaborator

Bonumose, Inc.

UNKNOWN

collaborator

Gelderse Vallei Hospital

OTHER

lead

Wageningen University

OTHER